Orphan designation: research and development

The European Medicines Agency provides support, including regulatory guidance and incentives, for the research and development of medicines for rare diseases in the European Union (EU).

In this section

In other sections

Sponsors of designated orphan medicines should also consider the regulatory information in the sections below:

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating
3 ratings
5 ratings